Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ossur Hf : Transactions in relation to share buyback program


Posted on: 30 Apr 18

Announcement no. 55/2018

17 September 2018 

Transactions in relation to share buyback program

On 5 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018.

The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 28 February 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.

The following transactions have been made under the program in week 28, the period 10 September 2018 - 14 September 2018:

Transactions
Date   No. of shares   Avg. purchase
price in DKK
  Transaction
value in DKK
10 September 2018   9,104   28.91   263,184
11 September 2018   15,377   29.04   446,620
12 September 2018   2,896   29.80   86,301
13 September 2018   119,492   30.41   3,633,274
14 September 2018   60,156   30.80   1,852,786
Total    207,025   30.34   6,282,165

 

Össur has acquired 1,465,669 shares under the program at the average price of DKK 28.52. Following the above transactions Össur's holding of own shares is 5,584,400 corresponding to 1.30% of the Company's total share capital.

The share buyback program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.

Further information

David Hreidarsson, Investor Relations, dohreidarsson@ossur.com, +354 515 1380

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors

About Össur

Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopaedics that helps people live a life without limitations.  Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports, prosthetic limbs and compression therapy.  A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, EMEA and APAC, with additional distributors worldwide. www.ossur.com.

 

Attachment

GlobeNewswire
globenewswire.com

Last updated on: 18/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.